{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007143","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.108620+00:00","generated_at":"2026-06-05T23:23:07.723094+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera cuts Ameluz transfer price to 25%, raises up to $16M in private placement","bullets":["Transfer price reduced from 50% to 25% for 2024-2025; stepwise increases to max 35% from 2032; minimum dollar amount per unit.","Company to assume control of all US clinical trials for Ameluz by June 1, 2024, improving cost management and oversight.","Private placement led by Rosalind Advisors: $8M from Series B-1 Preferred, plus $8M warrants tied to milestones; up to $16M gross.","Conversion price set at $0.7074 per share; Series B-3 conversion requires shareholder approval to increase authorized shares.","Net proceeds to fund general operations and accelerate development of additional Ameluz indications (BCC, SCC, acne)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007143","json":"https://secwatch.observer/filing/0001493152-24-007143.json","markdown":"https://secwatch.observer/filing/0001493152-24-007143.md","text":"https://secwatch.observer/filing/0001493152-24-007143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/0001493152-24-007143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:23:07.723094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"545a9fdbdb4f29bebd6a51cd6c78ecd73608948c","claim":"Biofrontera Inc. entered into Second Amended and Restated License and Supply Agreement with Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH valued at Transfer price changed to 25% through 2025 then increasing up to 35% starting in 2032 (effective 2024-02-13).","evidence_excerpt":"On February 19, 2024, Biofrontera Inc. (the “ Company ”) entered into the Second Amended and Restated License and Supply Agreement (the “ LSA ”), effective as of February 13, 2024 , by and among the Company, Biofrontera Pharma GmbH (“ Pharma ”), and Biofrontera Bioscience GmbH (“ Bioscience ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/0001493152-24-007143-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH"},{"label":"Value","value":"Transfer price changed to 25% through 2025 then increasing up to 35% starting in 2032"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}